US 12,419,842 B2
Controlled-release formulation for hearing loss and preparation method therefor
Dae-Jung Kang, Gyeonggi-do (KR); Gwangmin An, Gyeonggi-do (KR); Myung-Whan Suh, Seoul (KR); Hui Li, Seoul (KR); and Yu-Jung Hwang, Seoul (KR)
Assigned to MNH BIO CO., LTD, Gyeonggi-Do (KR); and SEOUL NATIONAL UNIVERSITY HOSPITAL, Seoul (KR)
Appl. No. 17/797,249
Filed by MNH BIO CO., LTD., Gyeonggi-do (KR); and SEOUL NATIONAL UNIVERSITY HOSPITAL, Seoul (KR)
PCT Filed Jan. 29, 2021, PCT No. PCT/KR2021/001248
§ 371(c)(1), (2) Date Aug. 3, 2022,
PCT Pub. No. WO2021/157968, PCT Pub. Date Aug. 12, 2021.
Claims priority of application No. 10-2020-0012749 (KR), filed on Feb. 3, 2020.
Prior Publication US 2023/0066553 A1, Mar. 2, 2023
Int. Cl. A61K 9/50 (2006.01); A61K 31/573 (2006.01); A61P 27/16 (2006.01)
CPC A61K 9/5036 (2013.01) [A61K 9/5089 (2013.01); A61K 31/573 (2013.01); A61P 27/16 (2018.01)] 19 Claims
 
1. A drug-controlled release formulation in which a steroidal anti-inflammatory agent encapsulated in microspheres of hyaluronic acid or hyaluronic acid salt is dispersed in an aqueous solution of hyaluronic acid or hyaluronic acid salt having a molecular weight of greater than 5,000,000 g/mol, and wherein the hyaluronic acid or hyaluronic acid salt is not crosslinked.